Immunologic effects of KD025 on human cGVHD. PBMCs from patients with active cGVHD were analyzed for their ability to produce (A) IL-21, (B) IL-17, and (C) IFNγ when treated with 2.5 μM, 10 μM, or DMSO vehicle for 48 hours. (D) The frequency of T follicular helper cells present and (E) expression of pStat3 normalized to actin, IRF4, and Bcl6 in samples treated with KD025, quantified in F, G, and H, respectively. *P < .05; **P < .01. Error bars represent standard deviation.